P045 | FIRST-LINE NIVOLUMAB-AVD FOR ADVANCED CLASSICAL HODGKIN LYMPHOMA IN ELDERLY PATIENTS: A SINGLE-CENTRE EXPERIENCE

Background The phase-III SWOG S1826 study established nivolumab-AVD (N-AVD) as a less-toxic, first-line option for advanced classical Hodgkin lymphoma (cHL), including patients ≥ 60 years. On the basis of those data, our centre introduced an attenuated-dose N-AVD programme for elderly or comorbid pa...

Full description

Bibliographic Details

Published in:	Haematologica
Main Authors:	T. Lazic, S. Luminari, A. Bavieri, S. Gambara, M. Nizzoli, L. Arletti, A. Ferrari, F. Ilariucci, F. Merli.
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2025-09-01
Online Access:	https://haematologica.org/article/view/12542